Janus Kinase Inhibitors in Autoimmune Diseases

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2013 Mar 28

PMID 23532440

Citations 173

Authors

John J OShea

Apostolos Kontzias

Kunihiro Yamaoka

Yoshiya Tanaka

Arian Laurence

Affiliations

Soon will be listed here.

Abstract

Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been approved by the FDA. It is therefore timely to consider this new category of drugs and reflect on their potential roles, present and future, in the treatment of RA and related disorders.

Citing Articles

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

Yang Y, Cathelin S, Liu A, Subedi A, Maher A, Hosseini M Nat Commun. 2025; 16(1):2384.

PMID: 40064887 PMC: 11894142. DOI: 10.1038/s41467-025-57614-y.

Remote-Customized Telecontrol for Patients with Rheumatoid Arthritis: The iARPlus (Innovative Approach in Rheumatology) Initiative.

Salaffi F, Farah S, Di Donato E, Sonnati M, Filippucci E, De Angelis R J Pers Med. 2025; 15(1).

PMID: 39852222 PMC: 11766830. DOI: 10.3390/jpm15010030.

Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.

Garcia-Porrua C, Heras-Recuero E, Blazquez-Sanchez T, Torres-Rosello A, Castaneda S, Gonzalez-Gay M J Clin Med. 2024; 13(21).

PMID: 39518631 PMC: 11546695. DOI: 10.3390/jcm13216492.

Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform.

Alvarez K, Cruz J, Giraldo L, Orozco V, Vasquez G, Rojas-Lopez M Nanomedicine (Lond). 2024; 20(1):9-22.

PMID: 39469848 PMC: 11730121. DOI: 10.1080/17435889.2024.2415877.

Cytokines in gingivitis and periodontitis: from pathogenesis to therapeutic targets.

Neurath N, Kesting M Front Immunol. 2024; 15:1435054.

PMID: 39253090 PMC: 11381234. DOI: 10.3389/fimmu.2024.1435054.

References

LaBranche T, Jesson M, Radi Z, Storer C, Guzova J, Bonar S . JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012; 64(11):3531-42. DOI: 10.1002/art.34649. View

McInnes I, Schett G . The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365(23):2205-19. DOI: 10.1056/NEJMra1004965. View

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View

Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B . A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26(1):127-32. DOI: 10.1038/nbt1358. View

Candotti F, Oakes S, Johnston J, Giliani S, Schumacher R, Mella P . Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood. 1997; 90(10):3996-4003. View

Yoshida K, van den Berg T, Dijkstra C . The functional state of follicular dendritic cells in severe combined immunodeficient (SCID) mice: role of the lymphocytes. Eur J Immunol. 1994; 24(2):464-8. DOI: 10.1002/eji.1830240230. View

Sims J, Smith D . The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010; 10(2):89-102. DOI: 10.1038/nri2691. View

Sandborn W, Ghosh S, Panes J, Vranic I, Su C, Rousell S . Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367(7):616-24. DOI: 10.1056/NEJMoa1112168. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Liew S, Nichols K, Klamerus K, Li J, Zhang M, Foulks G . Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012; 119(7):1328-35. DOI: 10.1016/j.ophtha.2012.01.028. View

11.

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

12.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

13.

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

14.

Kremer J, Bloom B, Breedveld F, Coombs J, Fletcher M, Gruben D . The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60(7):1895-905. DOI: 10.1002/art.24567. View

15.

Stump K, Lu L, Dobrzanski P, Serdikoff C, Gingrich D, Dugan B . A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther. 2011; 13(2):R68. PMC: 3132063. DOI: 10.1186/ar3329. View

16.

Rosengren S, Corr M, Firestein G, Boyle D . The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2011; 71(3):440-7. DOI: 10.1136/ard.2011.150284. View

17.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell C, Bradley J . Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367(6):495-507. DOI: 10.1056/NEJMoa1109071. View

18.

Verstovsek S, Kantarjian H, Mesa R, Pardanani A, Cortes-Franco J, Thomas D . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12):1117-27. PMC: 5187954. DOI: 10.1056/NEJMoa1002028. View

19.

Jacob N, Stohl W . Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228. PMC: 3239336. DOI: 10.1186/ar3349. View

20.

Crow M . Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther. 2011; 12 Suppl 1:S5. PMC: 2991778. DOI: 10.1186/ar2886. View